- Science-driven biopharmaceutical company focused on developing novel differentiated therapeutics for patients with osteoporosis as well as other serious endocrine-mediated diseases.
- Re-tread, which originally scheduled its IPO for November '13. Re-treads generally don't perform well in the IPO aftermarket.
- High cash burn rate, indicated by a price/earnings multiple of -6.4. A lower absolute number is worse.
- Any negative price/earnings ratio with an absolute number below -10 is a cause for concern.